Capmatinib is an oral, ATP-competitive, and highly potent, type 1b MET inhibitor.
| INTRODUC TI ON
Dysregulation of MET signaling leads to activation of downstream pathways that include the RAS/MAPK, PI3K/AKT, and Rac/Rho pathways, promoting cell proliferation, survival, and metastasis. 1 MET dysregulation, through gene amplification, mutation, and/or overexpression has been described in multiple tumor types, including lung, HCC, GBM, pRCC, breast, colon, and gastric cancers. 1 High-level MET gene amplification was originally described in gastric cancer cell lines, 2 resulting in increased mRNA and protein overexpression. 3 In EGFRwt, NSCLC de novo MET amplification has been reported in 1% to 4% of newly diagnosed cases. [4] [5] [6] MET amplification is also implicated in the acquired resistance to EGFR TKI, reported in 5% to 26% of cases, regardless of the presence of the T790M mutation. [7] [8] [9] [10] [11] [12] [13] In addition, MET mutations have been identified in primary tumors as well as in metastatic lesions of several cancers, including head and neck, pRCC, liver, ovarian, and NSCLC. 14, 15 In NSCLC, splice site alterations at exon 14 that lead to reduced internalization and degradation and net overexpression occur in 2% to 3% of adenocarcinomas [16] [17] [18] [19] and in up to 22% of sarcomatoid NSCLC. 20 Elevated levels of the receptor ligand HGF and/or overexpression of MET is often associated with resistance to chemotherapy and radiotherapy. 21 Overall, MET dysregulation is recognized as a negative prognostic factor, especially in advanced NSCLC [22] [23] [24] and is also associated with poor clinical outcomes in patients with glioblastoma and squamous cell carcinoma of the head and neck. 25, 26 Several MET inhibitors, comprising small molecule TKI and mAb targeting MET or its ligand, HGF, have been developed. 27 TKI are mainly divided into three types (I, II, and III) depending on binding of ATP to the MET kinase domain. 28, 29 The apo-MET kinase adopts a distinctive autoinhibitory conformation (activation loop locks into the ATP binding site through a salt bridge between D1228 and K1110). Type I MET inhibitors are ATP-competitive, and bind to MET unique autoinhibitory conformation (π-stacking with Y1230 in the MET activation loop). Type I inhibitors are further divided into type Ia and type Ib. Potency of type Ia inhibitors is due to interaction with Y1230, the hinge, and the solvent front glycine residue G1163 (analogous to the same position as ALK G1202 and ROS1 G2032), whereas type Ib MET inhibitors have stronger interactions with Y1230 and the hinge, but not with G1163. Thus, type Ib inhibitors are highly specific for MET with fewer off-target effects compared with type Ia inhibitors. Type II inhibitors are ATP-competitive, but bind to the ATP adenine binding site extending to the hydrophobic back pocket. They distort the apo-MET autoinhibitory conformation and bind to an induced conformation. They do not have interaction with G1163. Type III inhibitors bind to allosteric sites different from the ATP binding site. 28 Capmatinib (INC280) is an oral, ATP-competitive and highly potent type 1b MET inhibitor in biochemical (IC 50 0.13 nmol/L) and cellular (IC 50 ~ 1 nmol/L) assays and has proven to be highly selective versus other kinases in large panels of biochemical and binding assays. 30, 31 Capmatinib caused regression of METdependent tumors at tolerable doses in animal models across a range of tumor types, including NSCLC, HCC, and GBM. 30, 31 MET dependency in such responsive tumor models was associated with MET gene amplification (NSCLC, HCC), MET exon 14 skipping mutation (NSCLC), marked MET overexpression without amplification (NSCLC), or coexpression of MET and its ligand HGF (GBM).
The present phase 1 dose-escalation study (NCT01324479) assessed the safety and tolerability of capmatinib in patients with advanced MET-positive solid tumors. We also report herein the safety and efficacy observed in expansion cohorts of patients with METdysregulated gastric cancer, HCC, and other tumors (including GBM and pRCC). Safety and efficacy results of the expansion cohort of patients with advanced NSCLC is reported separately (Schuler M et al; manuscript submitted).
| MATERIAL S AND ME THODS

| Study design and treatment
This was a phase 1, open-label, multicenter, nonrandomized, twopart study comprising dose-escalation and expansion parts including patients with gastric cancer, HCC, and other solid tumor indications. In the first part of the study, molecularly prescreened patients with MET-dysregulated advanced solid tumors were enrolled in the dose-escalation phase. In the expansion phase, patients with solid tumors, including NSCLC, were enrolled based on MET dysregulation. Later, an additional expansion group was implemented to enrol patients with EGFRwt NSCLC preselected centrally (ClinicalTrials.gov Identifier: NCT01324479). based on a high MET expression (IHC score 3+); results for the original NSCLC expansion group and additional expansion group are reported separately (Schuler M et al; manuscript submitted).
The primary objective of the present study was to determine the MTD/RP2D of oral capmatinib based on the incidence, frequency, and category of DLT in cycle 1 and the AE. A two-parameter BLRM using the EWOC principle 32, 33 was used to guide the dose escalation for determination of the MTD or RP2D. Dose escalation was based on the incidence of DLT during cycle 1, with additional analyses carried out if significant toxicities were observed during later cycles (criteria for DLT provided in Table S1 ). After completion of a given cohort, the decision to dose escalate and the actual dose chosen depended on risk assessment calculations using the BLRM and medical review of available clinical and laboratory data, and the BLRM estimated the MTD by updating estimates of the probability of observing a DLT in the first cycle.
For a given schedule, the MTD was defined as the highest drug dosage not expected to lead to DLT in >33% of patients in the first 28 days.
The key secondary endpoint was ORR by investigator assessment, defined as the proportion of subjects with measurable disease whose best overall response is either complete response or partial response according to the RECIST v1.1 or MacDonald criteria (only for GBM).
Other secondary objectives were to further characterize antitumor activity, safety and tolerability, PK and PD (paired biopsies; IHC of p-MET, phospho-ERK, phospho-AKT, and phospho-S6, PK parameters), and DCR (proportion of patients whose best overall response is either complete response or partial response or stable disease).
In the dose-escalation part, separate cohorts of patients received treatment with increasing doses of capmatinib, starting at 100 mg bid in capsule formulation. PK and safety data from a tablet safety cohort were also used to guide the calculation of a tablet dose that would achieve comparable exposure to that of the RP2D of capmatinib capsules and meet the EWOC criteria in the BLRM for tablet. In the dose-expansion cohorts, patients were treated at a capmatinib dose of 600 mg bid, which is the RP2D of capmatinib capsules as determined in the safety cohort. Patients were permitted to switch to the 400 mg bid tablet dose. Patients were treated in 28-day cycles provided there was no evidence of disease progression or excessive toxicity and were continually reassessed for evidence of acute and cumulative toxicity.
| Patients
Adult patients (aged ≥18 years) with advanced solid tumors that are refractory to currently available therapies or for whom no effective treatment is available were eligible. Patients were required to have an ECOG Performance Status ≤2 and locally or centrally confirmed MET dysregulation as follows: for NSCLC, nasopharyngeal cancer, triple-negative breast cancer, pRCC, gastric cancer, and any other type of solid tumor, a MET H-score ≥150 or a ratio of MET/centromere ≥2.0 or MET GCN ≥5, or ≥50% of tumor cells with IHC score 2+ or score 3+; for HCC and GBM, a MET H-score ≥50 or a ratio of MET/centromere ≥2.0 or MET GCN ≥5. Patients with pRCC and germline MET mutation (in local report) were eligible. Key exclusion criteria were symptomatic CNS metastases that are neurologically unstable or requiring increasing doses of steroids to control; prior therapy with MET inhibitors or HGF-targeted therapy; or any CNS deficits (for GBM, CNS symptoms grade 2 or greater).
| Clinical assessments
Tumor lesions were assessed according to the RECIST v1.0 (investigator confirmed) or MacDonald criteria for patients with GBM.
CT-based tumor assessments were carried out unless contraindicated or for GBM, in which case MRI with contrast was carried out.
Assessments were carried out at screening, every 8 weeks beginning at the start of cycle 3 and as required to confirm response, and at the end of treatment (if no scan within 30 days prior to end of treatment). Safety assessments were carried out based on all AE, clinical laboratory data, and physical examinations.
| Pharmacokinetics analysis
During the phase 1 dose-escalation part of the study, pre-dose and 0.5, 1, 2, 4, 6, and 8 h post-dose PK samples were collected on cycle 1 day 1 and on cycle 1 day 15; pre-dose PK samples were collected on cycle 1 day 2, cycle 1 day 16, cycle 2 day 1, and cycle 3 day 1.
During the phase 1 dose-expansion part of the study, pre-dose and 0.5, 1, 2, 4, 6, and 8 h post-dose PK samples were collected on cycle 1 day 15 in non-NSCLC patients; pre-dose PK samples were collected on cycle 1 day 16 and cycle 2 day 1. Capmatinib concentrations in plasma were measured using a validated LC-MS/MS method with a lower limit of quantification of 1 ng/mL. Noncompartmental PK analysis was done to generate PK parameters of capmatinib, and dose proportionality of capmatinib was assessed.
| Statistical analysis
Data cutoff date for this report was July 17, 2017 when all patients had discontinued. No formal statistical power calculations to determine sample size were carried out for this study. It was estimated that a minimum of 15 subjects would be enrolled in the dose-escalation phase, including at least six subjects treated at the MTD/RP2D level. During the expansion phase, subjects with HCC, NSCLC, or gastric cancer were enrolled into separate groups of 10 subjects each. Each of these three groups could be expanded 
| Study oversight
This study was carried out in accordance with the Declaration of Helsinki and the principles of Good Clinical Practice. The protocol was approved by an Institutional Review Board at each hospital or site, and all patients provided written informed consent before any study procedures. The study was designed by the sponsor (Novartis Pharma AG). Data were collected and analyzed by the sponsor in conjunction with the authors. 
| RE SULTS
| Dose determination
Starting dose for dose escalation of this study was 100 mg bid as capsules. The bid regimen was selected based on the half-life of capmatinib 
| Safety
The most frequent AE (all grades, >30%) in the dose-escalation part regardless of causality were decreased appetite (42%), peripheral edema (40%), vomiting (40%), and nausea (37%) ( Table S2 ). The most frequent grade 3 or 4 AE (>5%) regardless of causality were increase in levels of blood bilirubin (11%), fatigue (8%), and AST increase (8%). The most common AE (all grades, >20%) suspected to be study drug-related were nausea (32%), decreased appetite (29%), vomiting (29%), fatigue (26%), and peripheral edema (21%) ( Table 3) . Study drug-related grade 3 or 4 AE were rare. The most commonly reported AE were fatigue (8%), ALT increase, and hypophagia (both 5%).
In the selected cohorts of the dose-expansion part of the study, the most frequent AE (all grades, >30%) regardless of causality were nausea (42%), peripheral edema (39%), and fatigue (34%) ( Table S2 ).
The most frequent grade 3 or 4 AE regardless of causality were fatigue (8%), nausea, AST increase, anemia, ascites, bilirubin increase, constipation, and ALT increase (all 5%).
Nausea (29%), peripheral edema (26%), and fatigue (24%) were the most common AE suspected to be study drug-related (Table 3) .
ALT and lipase increases were the most commonly reported grade 3 or 4 AE suspected to be study drug-related (both 5%).
| Efficacy
Efficacy was reported according to the investigator's assessment.
In the dose-escalation part of the study, at the data cutoff date of July 17, 2017, stable disease was reported in 10 of 38 (26%) patients (Table 4 ). In the dose-escalation part, tumor shrinkage was observed in two patients (colon cancer and HCC) treated at 450 mg bid (capsule) dose level.
Efficacy results in the expansion cohorts of patients with gastric cancer, HCC, and other solid tumors (non-NSCLC including GBM and pRCC) are presented in Table 4 . In these cohorts, stable disease was reported in two of nine (22%) patients with gastric cancer, five of 11 (46%) patients with HCC, and five of 18 (28%) patients with other advanced solid tumor types. Tumor reduction was reported in a number of patients; of note, two other solid tumor patients with GCN ≥6 achieved substantial tumor reduction ( Figure 1 ). Duration of response for evaluable patients by disease cohorts is shown in Figure S1 .
| Pharmacokinetics analysis
Capmatinib was rapidly absorbed after oral dose, with median time to peak plasma concentration (T max ) ranging from 1 to 4 h for capsules and approximately 2 h for tablets following single and multiple doses ( Table 5 ).
Steady-state AUC tau and C max of capmatinib were generally dose proportional across the dose range from 100 to 600 mg bid for the capsules ( Table 5 ). The drug accumulation ratio following multiple doses generally ranged from one-to twofold for the capsules, with more accumulation observed at 450 and 600 mg bid (ca. twofold).
Limited drug accumulation was observed with 400 mg bid tablets (Table 6) .
Tablet formulation at 400 mg bid provided comparable mean exposures to the capsules at 600 mg bid ( 
| Pharmacodynamic data
Capmatinib PD activity in inhibiting the MET pathway was shown in paired biopsies collected from a patient with advanced CRC. Nearcomplete p-MET inhibition (as determined by IHC; H-score = 2) was shown following capmatinib at 450 mg bid in capsule formulation at cycle 1 day 15 ( Figure S2 ). Overall, capmatinib was well tolerated at the RP2D (600 mg bid capsule and 400 mg bid tablet). The most common AE suspected to be related to the study drug were mostly grade 1 or 2.
| D ISCUSS I ON
Only a limited number of patients were determined to have tumors harboring high-level MET gene copy gain or high MET overexpression or MET mutations in both the escalation and selected expansion cohorts.
Although the best overall response was limited with stable disease in 26%
of escalation patients and in 32% of the expansion patients (22% of patients in the gastric cancer cohort, 46% of patients in the HCC cohort, and 28% of patients with other advanced solid tumor types), a number of these patients achieved substantial tumor reduction and durable stable disease; of note, two other solid tumor patients with GCN ≥6 achieved substantial tumor reduction ( Figure 1) . These results were similar to those observed with capmatinib with Japanese patients with advanced solid tumors, where the best overall response was stable disease (reported in 18.2% of patients). 34 Abbreviations: AUC 0-12 h , area under concentration-time curve from time 0 to 12 h; bid, twice daily; C max , maximum observed plasma concentration; CV%, percent coefficient of variation; T max , median time to peak plasma concentration; PK, pharmacokinetics.
TA B L E 6
Summary of accumulation ratio for capmatinib following repeated dosage Abbreviations: bid, twice daily; CV%, percent coefficient of variation; PK, pharmacokinetics; Racc, mean accumulation ratio; ss, at steady state.
Overall, in the present study, suboptimal molecular selection for MET status might have contributed to the limited efficacy observed in both the escalation and the expansion cohorts of patients with gastric cancer, HCC, and other solid tumors. In summary, the RP2D of capmatinib was 600 mg bid capsule or 400 mg bid tablet. The tablet formulation is now used in all capmatinib studies. Capmatinib was well tolerated and showed antitumor activity and acceptable safety profile at the R2PD.
Results
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